Comparison

PFKFB3 Antibody (N-term) Blocking Peptide

Item no. ABC-BP8145a
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Lyophilized
Specific against other
Citations Navarro-Sabate, A., et al., Gene 264(1):131-138 (2001).Chesney, J., et al., Proc. Natl. Acad. Sci. U.S.A. 96(6):3047-3052 (1999).Sakakibara, R., et al., J. Biochem. 122(1):122-128 (1997).Hamilton, J.A., et al., Mol. Endocrinol. 11(4):490-502 (1997).Sakai, A., et al., J. Biochem. 119(3):506-511 (1996).
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3,6PF-2-K/Fru-2,6-P2ase 3,PFK/FBPase 3,6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme,Renal carcinoma antigen NY-REN-56,iPFK-2,6-phosphofructo-2-kinase,Fructose-2,6-bisphosphatase,PFKFB3
Similar products PFKFB3, Fructose-2, 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3, 6PF-2-K/Fru-2, 6-P2ase brain/placenta-type isozyme, Renal carcinoma antigen NY-REN-56, iPFK-2, 6-phosphofructo-2-kinase, 6-bisphosphatase, PFK/FBPase 3, 6-P2ase 3
Available
Manufacturer - Category
Peptides; Blocking Peptides
Manufacturer - Targets
The synthetic peptide sequence used to generate the antibody AP8145a was selected from the N-term region of human PFKFB3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Bio Background
PFKFB (6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase) is a bifunctional enzyme, having both kinase and phosphatase activities residing on the same enzyme subunit but having distinct active sites. PFKFB regulates the steady-state concentration of fructose-2, 6-bisphosphate, a potent activator of a key regulatory enzyme of glycolysis, phosphofructokinase. To date, four PFKFB isozymes (PFKFB 1-4) have been described, which show differences in their tissue distribution and kinetic properties in response to allosteric effectors and hormonal signals. Among the PFKFB's PFKFB3 has the highest kinase:phosphatase ratio, in part because it lacks the characteristic serine phosphorylation site near the N-terminal that down-modulates kinase activity. PFKFB3 was first described in the rapidly growing placenta. The glucolitic rate in placenta is accelerated by anoxia and by maternal diabetes. Cancer cells maintain a high glycolytic rate even in the presence of oxygen, a phenomenon known as the Warburg effect. The glycolytic rate in the placenta, another fast-growing tissue, is accelerated by anoxia and by maternal diabetes.
Gene Name
PFKFB3
Subtitle
Synthetic peptide
Formulation
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close